CDK4/6 Inhibitors in Breast Cancer Elderly Patients: an Observational Ambispective Longitudinal Multicenter Study

Recruiting now

Conditions studied: Breast Cancer, Old Age

In brief

Breast cancer is one of the tumors with the highest incidence and current evidence indicates a higher prevalence in elderly patients (≥70 years) with a higher mortality rate due to immunosenescence, diagnostic delay and under treatment. Elderly patients are still poorly represented in clinical trials and the main indications for the treatment of the elderly population are extrapolated from the guidelines used in studies conducted predominantly on the younger population. In particular, these guidelines do not take into account the significant variability of elderly patients, in particular their comorbidities, performance status, physiological age and frailty. The aim of this study is to improve understanding of the clinical efficacy and safety of CDK 4/6i in older women in a real-world setting compared to younger women.

Key facts

Study ID

NCT07399808

Run by

Fondazione IRCCS Policlinico San Matteo di Pavia

People needed

100

Starts

2025-03-21

Expected to finish

2026-12-01

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age over 18 years
• patients with solid tumours undergoing active systemic treatment with CDK4/6 for adjuvant disease

You may not qualify if…

• Patients who are unable to understand informed consent document

Where it is running

• Fondazione IRCCS Policlinico San Matteo di Pavia — Pavia, Pavia, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.